Table 1 Modern landscape of triple and quadruple regimens in transplant eligible newly diagnosed multiple myeloma.
From: Long term responders in frontline multiple myeloma—exception vs expectation of the modern era
Feature | PETHEMA/GEM2012 [4] | IFM-2009 [5] | DETERMINATION [6] | CASSIOPEIA [7] | GRIFFIN [8] | GMMG-HD7 [9] | PERSEUS [10] | GMMG -CONCEPT [11] | IsKia [12] |
|---|---|---|---|---|---|---|---|---|---|
N | 458 | 700 | 722 | 898 | 203 | 662 | 709 | TE: 99 | 302 |
Phase of study | 3 | 3 | 3 | 3 | 2 | 3 | 3 | 2 | 3 |
Treatment combination | VRd | VRd +/− ASCT | VRd +/− ASCT | R1: DVTd vs VTd R2: Dara vs placebo | DVRd vs VRd | IsaVRd vs VRd | DVRd v VRd | IsaKRd | IsaKRd vs KRd |
Primary endpoint | PFS | PFS | PFS | R1: sCR p consolidation R2: PFS p maintenance | sCR p consolidation | R1: MRD- p induction R2: PFS p maintenance | PFS | MRD (-)10−5 | MRD (-)10−5 |
Induction/consolidation | 6/2 (28-day) | 3/2 (28-day) | 3/2 (21-day) | 4/2 (28-day) | 4/2 (21-day) | 3/0 (42-day) | 4/2 (28-day) | TE: 6/4 (28-day) | 4/4 (28-day) |
Maintenance duration | NR | Len 1 year | Indefinite | 2 years | 2 years | 3 years | Indefinite | Indefinite | NR |
Median follow-up (mo) | NR | 90 | 76 | 45 | 50 | NR | 48 | TE: 44 | 20 |
ORR (%) | 80.6 | NR | 98 vs 95 | 92 vs 90 | 99 vs 92 | 90 vs 84 | 97 vs 94 | TE: 95 | NR |
≥VGPR (%) | 76 | 78 vs 69 | 83 vs 80 | 83 vs 78 | 96 vs 77 | 77 vs 61 | 95 vs 89 | TE: 91 | 94 both |
Post-consolidation sCR (%) | 50 (CR) | NR | 33 vs 28 | 29 vs 20 | 42 vs 32 | 69 vs 45 | TE: 73 | 64 vs 67 | |
MRD(−) 10−4(%) | 66 | 79 vs 65 | NR | NR | NR | NR | NR | NR | NR |
MRD(−) 10−5 (%) | NR | NR | 55 vs 40 | NR | 64 vs 30 | NR | 75 vs 48 | NR | 77 vs 67 |
MRD(−) 10−6 (%) | NR | 30 vs 20 | NR | NR | 36 vs 16 | NR | 65 vs 32 | NR | 67 vs 48 |
P-induction 10−5 (%) | 29 (10−6) | NR | NR | NR | 22 vs 8 | 50 vs 36 | NR | NR | NR |
P-ASCT 10−5 (%) | 42 (10−6) | NR | NR | NR | NR | NR | NR | NR | NR |
P-consolidation 10−5 (%) | 66 (10−4) | NR | NR | 57 vs 37 | 50 vs 20 | NR | NR | 68 vs 54 | 77 vs 67 |
P-maintenance 10−5 (%) | NR | NR | NR | NR | 64 vs 30 | NR | NR | 82 vs 69 | NR |
MRD(−) 10−5 ≥ 12 mo | NR | NR | NR | NR | NR | NR | 65 vs 30 | 63 vs 46 | NR |
4-year PFS (%) | NR | NR | NR | NR | 87 vs 70 | NR | 84 vs 68 | NR | NR |
Median PFS (mo) | NR | 47 vs 35 | 68 vs 46 | NR vs 47 | NR vs NR | NR | NR | ||
OS (%) | NR | 62 vs 60 (8-year) | 81 vs 79 (5-year) | NR | NR | NR | NR | NR | NR |
